Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
Researchers at Hera Therapeutics have developed a therapy that blocks replication of high-risk HPV types, including HPV-16 and HPV-18, which cause 70% of cervical cancer. The company is developing a topical approach to treat HPV infection, offering hope to millions of women infected with these high-risk strains.